Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23242497 | 0.86 | TDP1 (0.45) | TDP1MAPTALDH1A1L3MBTL1NPC1 | |
| SCHEMBL24518268 | 0.80 | MAPT (0.48) | MAPTALDH1A1L3MBTL1FFAR4HSP90AA1 | |
| SCHEMBL11942099 | 0.78 | HSPB1 (0.42) | TDP1MAPTALDH1A1L3MBTL1FFAR4 | |
| SCHEMBL539834 | 0.78 | TDP1 (0.47) | TDP1MAPTALDH1A1L3MBTL1SIRT6 | |
| SCHEMBL31548078 | 0.78 | SIRT6 (0.56) | TDP1MAPTALDH1A1L3MBTL1TSHR | |
| SCHEMBL137523 | 0.78 | SIRT6 (0.56) | TDP1MAPTALDH1A1L3MBTL1TSHR | |
| SCHEMBL8812343 | 0.77 | TDP1 (0.62) | TDP1MAPTALDH1A1L3MBTL1NPC1 | |
| SCHEMBL1958524 | 0.77 | FFAR4 (0.41) | TDP1MAPTALDH1A1L3MBTL1FFAR4 | |
| SCHEMBL8067121 | 0.77 | MAPT (0.51) | TDP1MAPTALDH1A1L3MBTL1NPC1 | |
| SCHEMBL1342267 | 0.77 | MAPT (0.55) | TDP1MAPTALDH1A1L3MBTL1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4048667-B1 | 3-(4-(11H-DIBENZO[B,E][1,4]AZEPIN-6-YL)PIPERAZIN-1-YL)- AND 3-(4-(DIBENZO[B,F][1,4]OXAZEPIN/THIAZEPIN/DIAZEPIN-11-YL)PIPERAZIN-1-YL)-PROPANOIC ACID DERIVATIVES AS H1 AND 5-HT2A-RECEPTOR MODULATORS FOR THE TREATMENT OF SLEEP DISORDERS | ALAIRION INC (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-4048667-A1 | 3-(4-(11H-DIBENZO[B,E][1,4]AZEPIN-6-YL)PIPERAZIN-1-YL)- AND 3-(4-(DIBENZO[B,F][1,4]OXAZEPIN/THIAZEPIN/DIAZEPIN-11-YL)PIPERAZIN-1-YL)-PROPANO IC ACID DERIVATIVES AS H1 AND 5-HT2A-RECEPTOR MODULATORS FOR THE TREATMENT OF SLEEP DISORDERS | Alairion, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| CN-114929688-A | 3- (4- (11H-dibenzo [ b, e ] [1,4] azepin-6-yl) piperazin-1-yl) -and 3- (4- (dibenzo [ b, f ] [1,4] oxazepin/thiazepin/diazepin-11-yl) piperazin-1-yl) -propionic acid derivatives as H1 and 5-HT 2A-receptor modulators for the treatment of sleep disorders | 阿莱瑞恩公司 | 2022-08-19 | — | — | CN | disclosed |
| US-11046651-B2 | Piperazine substituted azapine derivatives and uses thereof | ALAIRION, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046651-B2 | Piperazine substituted azapine derivatives and uses thereof | ALAIRION, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| WO-2021080997-A1 | 3-(4-(11H-DIBENZO[B,E][1,4]AZEPIN-6-YL)PIPERAZIN-1-YL)- AND 3-(4-(DIBENZO[B,F][1,4]OXAZEPIN/THIAZEPIN/DIAZEPIN-11-YL)PIPERAZIN-1-YL)-PROPANO IC ACID DERIVATIVES AS H1 AND 5-HT2A-RECEPTOR MODULATORS FOR THE TREATMENT OF SLEEP DISORDERS | ALAIRION, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| US-20210114989-A1 | PIPERAZINE SUBSTITUTED AZAPINE DERIVATIVES AND USES THEREOF | Neumora Therapeutics, Inc. | 2021-04-22 | — | — | US | disclosed |
| US-20210114989-A1 | PIPERAZINE SUBSTITUTED AZAPINE DERIVATIVES AND USES THEREOF | Neumora Therapeutics, Inc. | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046651-B2 | Piperazine substituted azapine derivatives and uses thereof | HTR2A, HTR5A, HTR2C | TDP1 1163/4885MAPT 3698/4885ALDH1A1 751/4885 |
| US-20210114989-A1 | PIPERAZINE SUBSTITUTED AZAPINE DERIVATIVES AND USES THEREOF | HTR2A, HTR5A, HTR2C | TDP1 1163/4885MAPT 3698/4885ALDH1A1 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.